Key clinical point: Adding olanzapine to aprepitant, palonosetron, and dexamethasone (APD) provided better control of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy.

Major finding: A 5 mg dose of olanzapine plus APD produced a significantly higher complete response rate in the delayed phase (24 hours to 120 hours) than APD plus placebo — 79% and 66%, respectively.

Study details: Phase 3 trial of 710 patients with malignant solid tumors.

Disclosures: The study was sponsored by the Japan Agency for Medical Research and Development (AMED). Mr. Hashimoto had nothing to disclose. Senior authors on the paper reported relationships with numerous pharmaceutical companies.